Home » Headlines » Currently Reading:

Morning Headlines 9/16/24

September 15, 2024 Headlines No Comments

Ozempic Is Selling So Well An Insurer Wants $1 Million In Payments Back

Elevance Health’s Anthem Blue Cross Blue Shield accuses physicians of falsifying patient medical records with the intention of getting the insurer to pay for improper prescribing of the diabetes drug Ozempic for weight loss, a use that is not approved by the FDA.

Phishing Email May Have Impacted Personal Information

Atrium Health notifies patients that an unauthorized third party gained access to multiple employee email accounts in a two-day phishing attack.

Nirvana Raises $24.2M Series A to Revolutionize Health Insurance Verification

Nirvana, a New York City-based startup specializing in AI-powered health insurance verification software, raises $24.2 million.

23andMe settles data breach lawsuit for $30 million

23andMe will pay $30 million to settle a lawsuit that accused the company of failing to protect the records of 6.9 million of its users whose information was exposed in a 2023 breach.



HIStalk Featured Sponsors

     

Text Ads


RECENT COMMENTS

  1. Ageed Mike, "patients are the widgets that must be processed" additionally when it costs close to $3,700 a month for…

  2. The TSA-ification of every aspect of American society continues at pace. Race to the bottom, and technology amplifies the obvious…

  3. I dont think anything will change until Dr Jayne and others take my approach of naming names, including how much…

  4. My husband was in the ER, upon discharge we were handed discharge papers, after getting home we realized they were…

  5. I love the community health center that serves as my medical home, but they regularly ask me to sign forms…

Founding Sponsors


 

Platinum Sponsors


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gold Sponsors


 

 

 

 

 

 

 

 

RSS Webinars

  • An error has occurred, which probably means the feed is down. Try again later.